Of note, SLx-2119, that has 100-fold more selectivity towards ROCK2 than ROCK1, has been suggested to be a potential drug for the treatment of ischemic stroke [43], autoimmune disease [44,45] and psoriasis [46]. The gene discussed is ROCK1; the disease is ischemic stroke.